If you’re looking for mutual fund equity reporting funds, a place to start might be Fidelity Advisor Biotechnology I (FBTIX). FBTIX maintains a Zacks Mutual Fund Rating of 2 (Buy), based on nine predictive factors such as size, expense and past performance.
Fidelity is based in Boston, MA and is the manager of FBTIX. Since Fidelity Advisor Biotechnology I’s debut in December 2000, FBTIX has amassed more than $775.94 million in assets. Eirene Kontopoulos is the current manager of the fund and has held that role since July 2018.
Of course, investors want strong performance in the money. This fund in particular produced a 5-year annualized total return of 8%, and ranked in the bottom third of its category peers. If you’re looking for shorter time frames, don’t dismiss the fund’s 3-year annualized total return of 6.87%, which puts it in the middle third of that time frame.
When looking at a fund’s performance, it’s also important to note the standard deviation of returns. The lower the standard deviation, the lower the volatility of the fund’s experiences. FBTIX’s standard deviation over the past three years is 21.67% compared to the category average of 17.21%. The fund’s standard deviation over the past 5 years is 21.72 percent, compared to the category average of 15.41 percent. This makes the fund more volatile than its peers over the past half-decade.
Investors should note that the fund has a 5-year beta of 0.74, so it may be less volatile than the market. Alpha is an additional measure to consider, as it represents the portfolio’s risk-adjusted performance against a benchmark, in this case, the S&P 500. FBTIX’s 5-year performance produced a positive alpha of 0.73. This means that the managers in this portfolio are adept at selecting securities that generate better returns than the benchmark.
As competition heats up in the mutual fund market, costs become more important. A product with a lower price will be superior compared to another similar product, all other things being equal. Therefore, it is crucial for investors to keep a close eye on price-related metrics. In terms of fees, FBTIX is a no-load fund. It has an expense ratio of 0.73% compared to the category average of 1.30%. In terms of price, FBTIX is actually cheaper than its peers.
Investors should note that the minimum initial investment for the product is $0 and each subsequent investment has no minimum amount.
Overall, Fidelity Advisor Biotechnology I (FBTIX) has a high Zacks Mutual Fund Rank, and in combination with its relatively poor performance, low risk and low payouts, Fidelity Advisor Biotechnology I (FBTIX) seems to be the right choice for investors. right now.
Your research on the mutual fund equity report section should not stop here. For more information, you can visit www.zacks.com/funds/mutual-funds to view our great mutual fund tools. Be sure to visit Zacks.com for our full suite of tools to help you analyze the rest of your portfolio, researching all your stocks and funds in one place.
Looking for the latest recommendations from Zacks Investment Research? Today, you can download 7 best stocks for the next 30 days. Click here to get this free report.
Get your free (FBTIX): Financial Analysis Report
Click here to read this article on Zacks.com.
Zacks Investment Research